Clinical investigations involving human subjects and drugs, biologics, devices or test articles are subject to review. In order to comply with federal regulations, the IRB will determine what types of applications and exemptions (when applicable) are required for the study. This document describes various types of studies and instructions for submission and compliance.

This policy describes the process by which the IRB determines if risks are minimized for participants in a proposed project. Review process and relevant definitions are included in the document.

This policy outlines UAB's approach to determining whether use of commercially available cell lines is defined as human subjects research.

This policy details the process for reviewing and handling financial (or other) conflicts of interest surrounding the investigator of a proposed project.

This policy establishes UAB’s program for the protection of human subjects and describes the ethical standards and institutional commitments applicable to the conduct of human subjects research at UAB.

This document details specific biosafety guidelines for UAB laboratories and facilities that use biological agents.

This guideline describes the duties of the University Contracts Office. Information on services provided by the office and departmental responsibilities related to contracts are also included in the document.

This policy describes documentation requirements for the OIRB (Office of the IRB).

This policy explains UAB's commitment to its compliance with the DHHS Policy on Protection of Human Subjects.

This policy defines the circumstances that constitute an IRB member and consultant conflict of interest. Immediate family members, dependents, and anyone else who has a personal, professional, or financial tie with an IRB member or consultant may not be reviewed by that member or consultant.